Spironolactone potentiates the protective action of some selected antiepileptic drugs against maximal electroshock-induced seizures in mice

Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia

Volumn 22, Issue 1, 2009, Pages 123-134

  Kozińska, Justyna ^a   Sawicka, Katarzyna M ^a   Zadrozniak, Anna ^a   Wojda, Ewa ^a   Andres Mach, Marta ^b   Dudra Jastrzȩbska, Monika ^a,b   Łuszczki, Jarogniew J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; SPIRONOLACTONE; TOPIRAMATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG POTENTIATION; ELECTRIC SHOCK; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOUSE; MUSCLE STRENGTH; NONHUMAN; SEIZURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALIA; MUS;

EID: 77953443635     PISSN: 08670609     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10080-008-0167-x     Document Type: Article

References (24)

1. Boissier J. R., Tardy J., Diverres J. C.: Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basel), 3, 81, 1960.
2. Borowicz K. K., Czuczwar S. J.: Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats. J. Neural Transm., 112, 891, 2005.
3. Borowicz K. K., Czuczwar S. J.: Influence of aminoglutethimide and spironolactone on the efficacy of carbamazepine and diphenylhydantoin against amygdala-kindled seizures in rats. Eur. J. Pharmacol., 516, 212, 2005.
4. Brodie M. J., Schachter S. C.: Fast Facts. Epilepsy. 2nd ed., Health Press, 82, Oxford 2001.
5. Edwards H. E., Vimal S., Burnham W. M.: The acute anticonvulsant effects of deoxycorticosterone in developing rats: role of metabolites and mineralocorticoid-receptor responses. Epilepsia, 46, 1888, 2005.
6. Litchfield J. T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96, 99, 1949.
7. Löscher W., Fassbender C. P., Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 8, 79, 1991.
8. Łuszczki J. J., Czernecki R., Wojtal K. et al.: Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J. Neural Transm., 115, 1485, 2008.
9. Łuszczki J. J., Czuczwar S. J.: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 529, 2007.
10. Łuszczki J. J., Czuczwar S. J.: Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia, 45, 895, 2004.
11. Łuszczki J. J., Mohamed M., Czuczwar S. J.: 2-phosphonomethyl- pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol., 531, 66, 2006.
12. Łuszczki J. J., Ratnaraj N., Patsalos P. N. et al.: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshockinduced seizure model. Naunyn-Schmiedeberg's Arch. Pharmacol., 373, 169, 2006.
13. Łuszczki J. J., Sawicka K. M., Kozińska J. et al.: Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model. Epilepsy Res., 76, 66, 2007.
14. Łuszczki J. J., Sawicka K. M., Kozińska J. et al.: Amiloride enhances the anticonvulsant action of various antiepileptic drugs in the mouse maximal electroshock seizure model. J. Neural Transm., 116, 57, 2009.
15. Łuszczki J. J., Świa̧der M., Parada-Turska J. et al.: Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology, 28, 1817, 2003.
16. Łuszczki J. J., Wójcik-Ćwikła J., Andres M. M. et al.: Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole- induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology, 30, 958, 2005.
17. Patsalos P. N., Fröscher., Pisani F. et al.: The importance of drug interactions in epilepsy therapy. Epilepsia, 43, 365, 2002.
18. Pratt-Ubunama M. N., Nishizaka M. K., Calhoun D. A.: Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr. Hypertens. Rep., 7, 186, 2005.
19. Roberts A. J., Keith L. D.: Mineralocorticoid receptors mediate the enhancing effects of corticosterone on convulsion susceptibility in mice. J. Pharmacol. Exp. Ther., 270, 505, 1994.
20. Roberts A. J., Keith L. D.: Sensitivity of the circadian rhythm of kainic acid-induced convulsion susceptibility to manipulations of corticosterone levels and mineralocorticoid receptor binding. Neuropharmacology, 33, 1087, 1994.
21. Sarafidis P. A., Bakris G. L.: Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol., 52, 1749, 2008.
22. Sica D. A.: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev., 10, 23, 2005.
23. Sica D. A.: The risks and benefits of therapy with aldosterone receptor antagonist therapy. Curr. Drug Saf., 2, 71, 2007.
24. Venault P., Chapouthier G., de Carvalho L. P. et al.: Benzodiazepine impairs and betacarboline enhances performance in learning and memory tasks. Nature, 321, 864, 1986.